Earlier this month, the FDA backed an accelerated approval pathway for Regenxbio's gene therapy for Hunter syndrome, sending the company's shares soaring and reigniting optimism across the biotechnology sector. For investors, the decision raised a much bigger question: has one regulatory shift changed the outlook for gene therapy, or are the industry's deepest problems still unresolved?
From Biotech's Brightest Hope to Its Biggest Disappointment
A single FDA decision lifted a biotechnology company's market value by more than ten per cent in a single trading session.
The treatment had not changed. No new clinical data had been released. No scientific breakthrough had occurred. Yet investors suddenly viewed the entire gene therapy sector differently.
That shift followed the FDA's decision to support an accelerated approval pathway for Regenxbio's gene therapy for Hunter syndrome, reversing a position that had appeared far less favourable only months earlier.1 For many investors, the move represented more than a positive development for a single company. It raised the possibility that one of biotechnology's most troubled sectors may finally be receiving a second chance.
Only a few years ago, gene therapy was viewed as the future of medicine. Rather than managing symptoms, these therapies aim to address disease at its genetic source. For patients with devastating rare diseases, many of which are caused by mutations in a single gene, this represented something healthcare rarely offers: the possibility of correcting disease rather than simply living with it.2
Investors quickly recognised the opportunity. Billions of dollars flowed into the sector, driven by the promise of life-changing treatments and the prospect of exceptional returns. While rare disease populations are often small, successful therapies can command extraordinary prices. Novartis' Zolgensma launched at approximately $2.1 million per patient, while CSL Behring's Hemgenix entered the market at around $3.5 million, making it one of the most expensive medicines ever commercialised. Bluebird Bio's Lyfgenia and Skysona launched at around $3 million each.3
Data caveat: The figures above are launch list prices. The net amounts healthcare systems and insurers actually pay are frequently lower, reflecting confidential rebates and outcomes-based agreements that are not publicly disclosed. Headline prices should not be read as realised revenue per patient.
The investment thesis appeared straightforward. If a therapy could fundamentally change a patient's life, healthcare systems would be willing to pay a premium. Companies could therefore generate substantial revenues despite treating only a limited number of patients.
The reality proved far more complicated.
Developing gene therapies remained expensive, technically challenging and commercially risky. Manufacturing processes were difficult to scale, clinical trials often involved very small patient populations and reimbursement became increasingly contentious as prices climbed into the millions. While the science continued to advance, the economics became harder to justify.
Investor confidence gradually faded. Larger pharmaceutical companies began reassessing their commitment to the sector. Pfizer's exit from the gene therapy market reinforced concerns that scientific innovation alone was not enough to create sustainable commercial success.4
By the beginning of 2026, gene therapy had shifted from one of biotechnology's most exciting investment themes to one of its most questioned. The strain has not eased since. Only this week, barely a day after the Regenxbio reversal, Sangamo Therapeutics, once regarded as a pioneer in genetic medicine, filed for bankruptcy protection after years of financial pressure.5
Why the FDA Changed Everything
Unlike most industries, the value of a biotechnology company often depends less on current revenues and more on the probability of future approval.
A regulator's decision can therefore transform a company's prospects overnight.
This dynamic is particularly important in rare diseases, where traditional clinical trials are often difficult because patient populations are exceptionally small. Developers have long argued that regulators should be willing to accept alternative forms of evidence when evaluating therapies for these conditions.
Recent FDA actions suggest the agency may be becoming increasingly receptive to that argument.
The Regenxbio decision was accompanied by broader signals that regulators may be adopting a more flexible approach towards rare disease therapies, including greater openness to accelerated approval pathways and alternative trial designs.6 For investors, this matters enormously. If the probability of approval increases, the expected future value of a therapy rises alongside it.
Crucially, none of this requires the underlying science to change.
What changes is the likelihood that promising treatments successfully reach the market.
For a sector that has spent years battling regulatory uncertainty, that shift alone may be enough to alter investor sentiment.
Revival or False Dawn?
Yet it would be premature to declare gene therapy's problems solved.
Regulatory flexibility may improve the outlook for developers, but it does not eliminate the commercial challenges that have plagued the industry for years.
Sarepta's Elevidys demonstrates both the promise and complexity of the sector. The therapy offers new hope for patients with Duchenne muscular dystrophy, one of the most devastating genetic diseases. Yet discussions surrounding long-term efficacy, safety monitoring and reimbursement continue to shape its future.7
More broadly, gene therapy faces a unique economic challenge. Unlike traditional medicines that generate recurring revenue over many years, gene therapies are often designed as one-time treatments. While this is beneficial for patients, it places significant pressure on companies to recover years of research and development costs through a single administration.
As prices continue to climb into the millions, healthcare systems face increasingly difficult decisions around affordability and access. Regulators can approve a therapy, but they cannot force insurers or national health systems to pay for it.
The FDA's recent decisions have undoubtedly revived confidence across the sector. After years of setbacks, investors finally have a reason to believe the regulatory environment may be becoming more supportive. However, approval is only the first step. The companies that ultimately succeed will be those capable of proving not only that their therapies work, but that they can build sustainable businesses around them.
The FDA may have revived confidence in gene therapy. Whether it has revived the economics is a far more important question.
Footnotes
-
Reuters (opens in a new tab), US FDA reverses course on Regenxbio's rare-disease gene therapy, backs accelerated approval bid, 22 June 2026. ↩
-
McKinsey & Company (opens in a new tab), Gene therapy coming of age: Opportunities and challenges to getting ahead, October 2019 ↩
-
IntuitionLabs (opens in a new tab), Gene Therapy Pricing: The Economics of Million-Dollar Cures, 24 April 2026. (launch prices for Zolgensma, Hemgenix, Lyfgenia and Skysona). ↩
-
Fierce Biotech (opens in a new tab), After gene therapy exit, Pfizer locks in a global license to Beam's gene-editing candidate, 25 February 2026. ↩
-
BioPharma Dive (opens in a new tab), Sangamo holds a bankruptcy sale VCs; back a China-linked Beam competitor, 24 June 2026. ↩
-
STAT News (opens in a new tab), Even at a meeting in Rome, FDA shifts are top of mind for gene therapy field, 6 May 2026. ↩
-
Elevidys (opens in a new tab), Sarepta Therapeutics, product information for Elevidys (Duchenne muscular dystrophy gene therapy), as at 26 June 2026. ↩